Literature DB >> 26327576

Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules.

A Gandhimathi1, R Sowdhamini1.   

Abstract

The serotonin receptors, also known as 5-hydroxytryptamine (5-HT) receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels found in the central and peripheral nervous systems. GPCRs have a characteristic feature of activating different signalling pathways upon ligand binding and these ligands display several efficacy levels to differentially activate the receptor. GPCRs are primary drug targets due to their central role in several signal transduction pathways. Drug design for GPCRs is also most challenging due to their inherent promiscuity in ligand recognition, which gives rise to several side effects of existing drugs. Here, we have performed the ligand interaction study using the two prominent states of GPCR, namely the active and inactive state of the 5-HT2A receptor. Active state of 5-HT2A receptor model enhances the understanding of conformational difference which influences the ligand-binding site. A 5-HT2A receptor active state model was constructed by homology modelling using active state β2-adrenergic receptor (β2-AR). In addition, virtual screening and docking studies with both active and inactive state models reveal potential small molecule hits which could be considered as agonist-like and antagonist-like molecules. The results from the all-atom molecular dynamics simulations further confirmed that agonists and antagonists interact in different modes with the receptor.

Entities:  

Keywords:  5-HT2A receptor; agonist; antagonist; induced fit docking; molecular dynamics; scaffold similarity; virtual screening

Mesh:

Substances:

Year:  2015        PMID: 26327576     DOI: 10.1080/07391102.2015.1062802

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  7 in total

1.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 2.  "Selective" serotonin 5-HT2A receptor antagonists.

Authors:  Austen B Casey; Meng Cui; Raymond G Booth; Clinton E Canal
Journal:  Biochem Pharmacol       Date:  2022-04-04       Impact factor: 6.100

Review 3.  Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design.

Authors:  Shaherin Basith; Minghua Cui; Stephani J Y Macalino; Jongmi Park; Nina A B Clavio; Soosung Kang; Sun Choi
Journal:  Front Pharmacol       Date:  2018-03-09       Impact factor: 5.810

4.  Computational and biological evidences on the serotonergic involvement of SeTACN antidepressant-like effect in mice.

Authors:  Mariana G Fronza; Lucimar M Pinto Brod; Angela Maria Casaril; Manoela Sacramento; Diego Alves; Lucielli Savegnago
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

Review 5.  Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors.

Authors:  Damian Bartuzi; Agnieszka A Kaczor; Katarzyna M Targowska-Duda; Dariusz Matosiuk
Journal:  Molecules       Date:  2017-02-22       Impact factor: 4.411

Review 6.  Overcoming Depression with 5-HT2A Receptor Ligands.

Authors:  Agata Zięba; Piotr Stępnicki; Dariusz Matosiuk; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

7.  Mechanism Exploration of Arylpiperazine Derivatives Targeting the 5-HT2A Receptor by In Silico Methods.

Authors:  Feng Lin; Feng Li; Chao Wang; Jinghui Wang; Yinfeng Yang; Ling Yang; Yan Li
Journal:  Molecules       Date:  2017-06-26       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.